Highlights

  • Clearmind completed patient recruitment on 27 October 2026 for the first segment of Part B in its CMND-100 trial.
  • The Part B design uses two sequential single ascending dose cohorts of 80 mg and 160 mg, six patients each.
  • Clearmind closed its US$2.5 million purchase of a 51% stake in Charging Robotics on 6 September 2026.
  • A 1-for-8 reverse split took effect on 5 October 2026, cutting outstanding shares to about 507,404 from 4,059,227.

Clearmind Medicine Inc. (NASDAQ:CMND) has taken its lead candidate CMND-100 into patients, completing recruitment on 27 October 2026 for the first segment of Part B of its Phase 1/2a trial in moderate-to-severe alcohol use disorder (AUD).

The Vancouver-based developer of non-hallucinogenic neuroplastogen therapeutics reached the milestone after a busy few months that included an electric vehicle charging investment, another share consolidation and a fresh convertible note draw.

CMND-100 Shifts From Healthy Volunteers to AUD Patients

Part A of the study, in healthy volunteers, has been completed, and in August 2026 the trial's Data Safety Monitoring Board cleared progression to Parts B and C. Part B comprises two sequential single ascending dose cohorts at 80 mg and 160 mg, with six patients in each.

The study is assessing safety, tolerability and pharmacokinetics, along with early efficacy signals such as reduced alcohol craving, at Johns Hopkins and Yale in the United States and at Tel Aviv Sourasky and Hadassah medical centers in Israel. Chief Executive Officer Dr. Adi Zuloff-Shani described the step as a move to the patient population the company aims to help. Clearmind's intellectual property portfolio covers nineteen Patent families, including 32 granted patents.

A Majority Stake in Wireless EV Charging

Clearmind agreed on 31 August 2026 to acquire 51% of Charging Robotics Ltd. for US$2.5 million and closed the deal on 6 September 2026. Charging Robotics develops wireless charging systems delivering up to 10 kW for automated parking facilities, autonomous mobile platforms and robotaxi operations.

As a closing condition, Clearmind lent Charging Robotics US$1.5 million at 4% annual interest, repayable after three years, with an automatic extension if the Business lacks the Cash Flow to repay.

Quarterly Results, Share Consolidations and New Notes

For the third quarter of fiscal 2026, the three months ended 31 July 2026, Clearmind reported an IFRS net loss of US$0.91 million, narrower than US$1.31 million a year earlier. The nine-month loss widened to US$6.81 million from US$3.17 million as administrative costs rose. Cash stood at US$12.04 million on 31 July 2026.

Shares were consolidated 1-for-40 in December 2025, 1-for-10 in May 2026 and 1-for-8 effective 5 October 2026. On 16 October 2026, Clearmind gave notice to issue US$2.0 million in convertible notes for US$1.8 million, under agreements allowing up to US$10.0 million.

Funding Needs and Listing Standards Ahead

Management expects its cash to cover at least twelve months but says the company depends on significant future financing. It has also flagged a proposed US$5.0 million Nasdaq Market Value of listed securities standard, currently stayed; with its value near US$3.5 million on 8 September 2026, Clearmind said it could face delisting if the stay is lifted.